Synthetic Biologics Inc (NYSEAMERICAN:SYN) was the recipient of a significant decrease in short interest during the month of January. As of January 12th, there was short interest totalling 4,341,664 shares, a decrease of 1.7% from the December 29th total of 4,416,270 shares. Based on an average daily volume of 720,227 shares, the short-interest ratio is currently 6.0 days. Approximately 3.8% of the company’s stock are short sold.
A number of research firms have commented on SYN. Zacks Investment Research downgraded Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. BidaskClub downgraded Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th.
Shares of Synthetic Biologics (NYSEAMERICAN SYN) remained flat at $$0.41 during trading on Monday. The company had a trading volume of 245,500 shares, compared to its average volume of 788,318. The firm has a market capitalization of $53.64, a price-to-earnings ratio of -1.89 and a beta of 1.08. Synthetic Biologics has a 12 month low of $0.37 and a 12 month high of $1.05.
Several institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC increased its position in Synthetic Biologics by 312.1% in the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after acquiring an additional 183,120 shares during the period. Virtu Financial LLC increased its position in Synthetic Biologics by 256.1% in the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock valued at $152,000 after acquiring an additional 215,440 shares during the period. Finally, 683 Capital Management LLC acquired a new stake in Synthetic Biologics in the 4th quarter valued at approximately $762,000.
COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/19/synthetic-biologics-inc-syn-short-interest-update-2.html.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.